Table 2 Comparisons of the clinical characteristics and treatment duration in patients with and without residual lymph nodes on follow-up CT scan after 6 months of antituberculous therapy
Non-residual LN (n = 122) | Residual LN (n = 35) | P-value | |
|---|---|---|---|
Gender (male) | 27 (22.1%) | 11 (31.4%) | 0.269 |
Age (years, mean ± SD) | 43.96 ± 15.74 | 33.37 ± 13.36 | < 0.001 |
Previous history of TB | 9 (7.4%) | 4 (11.4%) | 0.488 |
Comorbidity | 28 (23.0%) | 3 (8.6%) | 0.089 |
Duration of lymphadenopathy (months, mean ± SD) | 9.36 ± 34.20 | 4.39 ± 10.95 | 0.187 |
Location of cervical lymph node | 0.769 | ||
Bilateral | 11 (9.0%) | 3 (8.6%) | |
Left side | 46 (37.7%) | 11 (31.4%) | |
Right side | 65 (53.3%) | 21 (60.0%) | |
Largest size of the lymph node (mm, mean ± SD) | 32.77 ± 23.31 | 36.77 ± 29.71 | 0.466 |
Results of the initial diagnostic work-up, n/Na | |||
Compatible with TB on CT scan, n/Na | 89/108 (82.4%) | 26/27 (96.3%) | 0.077 |
AFB positive, n/Na | 17/77 (22.1%) | 2/15 (13.3%) | 0.728 |
TB culture positive, n/Na | 27/63 (42.9%) | 7/14 (50.0%) | 0.768 |
TB PCR positive, n/Na | 90/117 (76.9%) | 26/33 (78.8%) | 1.00 |
Histologic findings indicative of TB, n/Na | 100/121 (82.6%) | 30/35 (85.7%) | 0.800 |
Paradoxical reaction during treatment | 32/122 (26.2%) | 5/35 (14.3%) | 0.178 |
Duration of anti-tuberculous therapy (months) | |||
Mean ± SD | 7.03 ± 2.40 | 11.82 ± 7.46 | < 0.001 |
Median, IQR | 6 (6–6) | 9 (8–12) | < 0.001 |
Recurrence after antituberculous therapy | 5/122 (4.1%) | 2/35 (5.7%) | 0.653 |